Investigational Drug Information for OSU-6162
✉ Email this page to a colleague
What is the drug development status for OSU-6162?
OSU-6162 is an investigational drug.
There have been 9 clinical trials for OSU-6162.
The most recent clinical trial was a Phase 2 trial, which was initiated on March 20th 2023.
The most common disease conditions in clinical trials are Recurrence, Stress Disorders, Traumatic, and Stress Disorders, Post-Traumatic. The leading clinical trial sponsors are Ohio State University, VA Office of Research and Development, and San Diego Veterans Healthcare System.
There are two US patents protecting this investigational drug and one hundred and twenty-three international patents.
Summary for OSU-6162
| US Patents | 2 |
| International Patents | 123 |
| US Patent Applications | 24 |
| WIPO Patent Applications | 14 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2023-03-20) |
| Vendors | 25 |
Recent Clinical Trials for OSU-6162
| Title | Sponsor | Phase |
|---|---|---|
| A Prospective, Exploratory Analysis of Immune and Inflammatory Response Associated With Clozapine | Ohio State University | Phase 4 |
| OSU6162 as add-on in SSRI/SNRI-resistant Depression | Arvid Carlsson Research AB | Phase 2 |
| OSU6162 as add-on in SSRI/SNRI-resistant Depression | Göteborg University | Phase 2 |
Clinical Trial Summary for OSU-6162
Top disease conditions for OSU-6162
Top clinical trial sponsors for OSU-6162
US Patents for OSU-6162
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| OSU-6162 | ⤷ Try a Trial | Treatments for restless legs syndrome | Pharmacia & Upjohn Company (Kalamazoo, MI) | ⤷ Try a Trial |
| OSU-6162 | ⤷ Try a Trial | Method for predicting activation energy using atomic fingerprint descriptor or atomic descriptor | Bioinformatics & Molecular Design Research Center (Seoul, KR) | ⤷ Try a Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for OSU-6162
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| OSU-6162 | Canada | CA2982898 | 2035-05-13 | ⤷ Try a Trial |
| OSU-6162 | European Patent Office | EP3294337 | 2035-05-13 | ⤷ Try a Trial |
| OSU-6162 | World Intellectual Property Organization (WIPO) | WO2016180879 | 2035-05-13 | ⤷ Try a Trial |
| OSU-6162 | Austria | AT201669 | 2011-04-17 | ⤷ Try a Trial |
| OSU-6162 | Australia | AU1986992 | 2011-04-17 | ⤷ Try a Trial |
| OSU-6162 | Australia | AU653837 | 2011-04-17 | ⤷ Try a Trial |
| OSU-6162 | Canada | CA2105666 | 2011-04-17 | ⤷ Try a Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
